ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Prevalence and Risk Factors of Plasma Adiponectin Deficiency: A Cross-Sectional Study in a Physical Examination Cohort from Southwest China.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Numerous studies have investigated adiponectin in disease populations, but no study has focused on the plasma adiponectin level, adiponectin deficiency, and its influencing factors in the population who have not yet developed disease symptoms. Methods: The data of physical examination subjects who completed adiponectin detection in our hospital from 2020 to 2024 were included. The adiponectin levels in different age, genders, and subgroups were analyzed, and the indicators under adiponectin deficiency (<4 µg/mL in men and <5 µg/mL in women) were compared. The factors that might affect adiponectin deficiency were further included in multivariate logistic regression analysis. The odds ratio (OR) and 95% confidence interval (CI) were calculated to understand the possible risk factors for adiponectin deficiency. Results: A total of 11829 subjects were included in the study, and the overall rate of adiponectin deficiency was 12.06%. The adiponectin level was generally higher in women; however, there were no significant differences among the subgroups of hypoproteinemia, low HDL-C, and anemia. Besides, hyperglycemia (OR: 2.02, 95% CI: 1.64-2.50), obesity (OR: 2.34, 95% CI: 1.87-2.91), hypertriglyceridemia (OR: 2.17, 95% CI: 1.89-2.48), low HDL-C (OR: 2.09, 95% CI: 1.66-2.65), increased PLT count (OR: 2.57, 95% CI: 1.57-4.50) and elevated ALT (OR: 1.48, 95% CI: 1.24-1.76) are associated with higher adiponectin deficiency. However, no significant associations were observed between adiponectin deficiency and gender, blood pressure, or elevated LDL-C. Conclusion: The adiponectin level is generally higher in women than in men except for subjects with anemia, hypoproteinemia, and low HDL-C. Overweight/obesity, hypertriglyceridemia, low HDL-C, hyperuricemia, hyperglycemia, elevated ALT, and increased PLT count may be the risk factors for adiponectin deficiency. When these risk factors are present, targeted adiponectin testing is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.